Showing 4631-4640 of 7766 results for "".
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&
- AAD Honors Philadelphia Physicians For Teamwork to Treat Patient with Leprosyhttps://practicaldermatology.com/news/aad-honors-philadelphia-physicians-for-teamwork-to-treat-patient-with-leprosy/2459891/The American Academy of Dermatology (AAD) has honored Carrie Kovarik, MD, FAAD, and Keith Hamilton, MD, as Patient Care Heroes for their collaboration to improve patient care. Both physicians teach and practice medicine at the Perelman School of Medicine at the University of Pennsylvania in Phila
- SkinBioTherapeutics Raises Capital to Broaden Applications for Skin Biome Technologyhttps://practicaldermatology.com/news/skinbiotherapeutics-raises-capital-to-broaden-applications-for-skin-biome-technology/2459894/SkinBioTherapeutics raised close to $2M to widen potential applications for their skin biome technology, the company reports. Derived from probiotic bacteria, SkinBioTherapeutics technology is being developed for use in cosmetics, infectio
- FDA Proposes Policy for New Competitive Generic Therapies Pathwayhttps://practicaldermatology.com/news/fda-proposes-policy-for-new-competitive-generic-therapies-pathway/2459896/The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs) creates a designation that can be granted to a company submitting an application for their
- New Guidelines Offer SRT Treatment Recommendations for Skin Cancers, Keloidshttps://practicaldermatology.com/news/new-guidelines-offer-srt-treatment-recommendations-for-skin-cancers-keloids/2459897/Superficial Radiation Therapy (SRT) should be first-line therapy for appropriate non-melanoma skin cancers in appropriate patients, according to new consensus guidelines<
- Rodan & Fields Takes on Teen Acne with Spotlesshttps://practicaldermatology.com/news/rodan-fields-takes-on-teen-acne-with-spotless/2459898/Rodan & Fields is launching Spotless, a patent-pending teen and young adult acne solution. The company is also updating its Unblemish R
- Sienna Biopharmaceuticals: Promising Topline Results for SNA-001 for Hair Removalhttps://practicaldermatology.com/news/sienna-biopharmaceuticals-promising-topline-results-for-sna-001-for-hair-removal/2459899/Topline results from the pivotal trial of Sienna Biopharmaceuticals’ SNA-001 show that the topical agent in conjunction with an 810nm diode laser was statistically superior compared to vehicle plus laser. In the study involving 65 male and female patients with white, gray, blonde, light red
- Study Shows 97% Cure Rate for Superficial Radiation Therapy for BCC and SCChttps://practicaldermatology.com/news/study-shows-97-cure-rate-for-superficial-radiation-therapy-for-bcc-and-scc/2459900/A new retrospective study shows a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC) on their lower extremities with SRT-100TM Superficial Radiation Therapy from Sensus Hea
- Two New Psoriasis Guidelines Address Comorbidities, Biologic Treatmenthttps://practicaldermatology.com/news/two-new-psoriasis-guidelines-address-comorbidities-biologic-treatment/2459901/The American Academy of Dermatology and the National Psoriasis Foundation have released two new guidelines outlining best practices for treating psoriasis with a focus on comorbidities and biologic treatment. Develo
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s